ArticleDialogues in clinical neuroscience2004
Treatment goals: response and nonresponse.
Article in Dialogues in clinical neuroscience, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam.Psychopharmacology · 2006Trial
- Learning optimal early decision treatment rules with multi-domain intermediate outcomes.Biometrics · 2026Article
- Effect of duloxetine on changes in serum proinflammatory cytokine levels in patients with major depressive disorder.BMC psychiatry · 2024Article
- Prevalence and associations of multiple hypnotic prescriptions in a clinical sample.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
- Copper release by MOF-74(Cu): a novel pharmacological alternative to diseases with deficiency of a vital oligoelement.RSC advances · 2024Article
- Changes in patient-reported outcomes during admission to a South African psychiatric facility.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2024Article
- Assessing the Efficacy and Safety of a Digital Therapeutic for Symptoms of Depression in Adolescents: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2023Article
- The Exposome and Nutritional Pharmacology and Toxicology: A New Application for Metabolomics.Exposome · 2023Article
- Enhanced Directed Random Walk for the Identification of Breast Cancer Prognostic Markers from Multiclass Expression Data.Entropy (Basel, Switzerland) · 2021Article
- Effective dose 50 method as the minimal clinically important difference: Evidence from depression trials.Journal of clinical epidemiology · 2021Article
- Why maximum tolerated dose?British journal of clinical pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychiatric symptomatology is often subjective, but it can be partly made more objective for the purposes of evaluation. Esquirol was the first modern psychiatrist to stress the need for a scientific approach to treatment evaluation. The kinetics of treatment is complex because different components of the clinical picture improve at a different pace. Assessment of treatment requires prior definition of end point, response, and nonresponse. Response is influenced by several factors, such as placebo effect, diagnostic category and subtypes, and patient heterogeneity. Treatment response may be predicted from clinical and biological parameters. This article lists the main causes of nonresponse, and suggests how to remedy them.
Indexed as
Identifiers
22034465PMC3181789What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.